These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 14976055)

  • 1. A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the FcgammaRIIA and FcgammaIIIA genes.
    Miescher S; Spycher MO; Amstutz H; De Haas M; Kleijer M; Kalus UJ; Radtke H; Hubsch A; Andresen I; Martin RM; Bichler J
    Blood; 2004 Jun; 103(11):4028-35. PubMed ID: 14976055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A human anti-D monoclonal antibody selected for enhanced FcgammaRIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies.
    Beliard R; Waegemans T; Notelet D; Massad L; Dhainaut F; Romeuf Cd; Guemas E; Haazen W; Bourel D; Teillaud JL; Prost JF
    Br J Haematol; 2008 Apr; 141(1):109-19. PubMed ID: 18279459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Rh D monoclonal antibodies (BRAD-3 and BRAD-5) cause accelerated clearance of Rh D+ red blood cells and suppression of Rh D immunization in Rh D- volunteers.
    Kumpel BM; Goodrick MJ; Pamphilon DH; Fraser ID; Poole GD; Morse C; Standen GR; Chapman GE; Thomas DP; Anstee DJ
    Blood; 1995 Sep; 86(5):1701-9. PubMed ID: 7655002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and safety of recombinant anti-RhD in healthy RhD-negative male volunteers.
    Bichler J; Spycher MO; Amstutz HP; Andresen I; Gaede K; Miescher S
    Transfus Med; 2004 Apr; 14(2):165-71. PubMed ID: 15113381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IgG-Mediated Immune Suppression to Erythrocytes by Polyclonal Antibodies Can Occur in the Absence of Activating or Inhibitory Fcγ Receptors in a Full Mouse Model.
    Bernardo L; Yu H; Amash A; Zimring JC; Lazarus AH
    J Immunol; 2015 Sep; 195(5):2224-30. PubMed ID: 26188060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clearance of red cells by monoclonal IgG3 anti-D in vivo is affected by the VF polymorphism of Fcgamma RIIIa (CD16).
    Kumpel BM; De Haas M; Koene HR; Van De Winkel JG; Goodrick MJ
    Clin Exp Immunol; 2003 Apr; 132(1):81-6. PubMed ID: 12653840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection of a human anti-RhD monoclonal antibody for therapeutic use: impact of IgG glycosylation on activating and inhibitory Fc gamma R functions.
    Sibéril S; de Romeuf C; Bihoreau N; Fernandez N; Meterreau JL; Regenman A; Nony E; Gaucher C; Glacet A; Jorieux S; Klein P; Hogarth MP; Fridman WH; Bourel D; Béliard R; Teillaud JL
    Clin Immunol; 2006; 118(2-3):170-9. PubMed ID: 16332457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and safety of roledumab, a novel human recombinant monoclonal anti-RhD antibody with an optimized Fc for improved engagement of FCγRIII, in healthy volunteers.
    Yver A; Homery MC; Fuseau E; Guemas E; Dhainaut F; Quagliaroli D; Beliard R; Prost JF
    Vox Sang; 2012 Oct; 103(3):213-22. PubMed ID: 22568808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clearance kinetics of autologous RhD-positive erythrocytes coated ex vivo with novel recombinant and monoclonal anti-D antibodies.
    Chapman GE; Ballinger JR; Norton MJ; Parry-Jones DR; Beharry NA; Cousins C; Dash CH; Peters AM
    Clin Exp Immunol; 2007 Oct; 150(1):30-41. PubMed ID: 17680827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced opsonisation of Rhesus D-positive human red blood cells by recombinant polymeric immunoglobulin G anti-G antibodies.
    Díaz-Solano D; Fuenmayor J; Montaño RF
    Blood Transfus; 2018 Feb; 16(2):200-208. PubMed ID: 28686149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-response relationship and pharmacogenetics of anti-RhD monoclonal antibodies.
    Ternant D; Ohresser M; Thomas C; Cartron G; Watier H; Paintaud G
    Blood; 2005 Aug; 106(4):1503-4; author reply 1504-5. PubMed ID: 16079438
    [No Abstract]   [Full Text] [Related]  

  • 12. Variation in IgG1 heavy chain allotype does not contribute to differences in biological activity of two human anti-Rhesus (D) monoclonal antibodies.
    Paterson T; Innes J; McMillan L; Downing I; Carter MC
    Immunotechnology; 1998 Jun; 4(1):37-47. PubMed ID: 9661813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers.
    Kumpel BM
    Vox Sang; 2007 Aug; 93(2):99-111. PubMed ID: 17683353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy.
    Hatjiharissi E; Hansen M; Santos DD; Xu L; Leleu X; Dimmock EW; Ho AW; Hunter ZR; Branagan AR; Patterson CJ; Kortsaris A; Verselis S; Fox E; Treon SP
    Clin Lymphoma Myeloma; 2007 Jan; 7(4):286-90. PubMed ID: 17324336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IgG Subclass Determines Suppression Versus Enhancement of Humoral Alloimmunity to Kell RBC Antigens in Mice.
    Shinde P; Howie HL; Stegmann TC; Hay AM; Waterman HR; Szittner Z; Bentlage AEH; Kapp L; Lissenberg-Thunnissen SN; Dekkers G; Schasfoort RBM; Ratcliffe SJ; Smolkin ME; Vidarsson G; van der Schoot CE; Hudson KE; Zimring JC
    Front Immunol; 2020; 11():1516. PubMed ID: 32765523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of genetic polymorphisms that predict responder/non-responder profiles to the RhD antigen.
    Tan JC; Armstrong NJ; Yuan FF; Flower RL; Dyer WB
    Mol Immunol; 2015 Dec; 68(2 Pt C):628-33. PubMed ID: 26505654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FcgammaRIIa-131R allele and FcgammaRIIIa-176V/V genotype are risk factors for progression of IgA nephropathy.
    Tanaka Y; Suzuki Y; Tsuge T; Kanamaru Y; Horikoshi S; Monteiro RC; Tomino Y
    Nephrol Dial Transplant; 2005 Nov; 20(11):2439-45. PubMed ID: 16221721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Fcgamma receptor IIa (cd32) gene polymorphism and anti-malarial IgG subclass antibodies to asexual blood-stage antigen of Plasmodium falciparum in an unstable malaria endemic area of Iran.
    Zakeri S; Mashhadi R; Mehrizi AA; Djadid ND
    Exp Parasitol; 2013 May; 134(1):115-21. PubMed ID: 23458236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor Profile.
    Bruggeman CW; Dekkers G; Bentlage AEH; Treffers LW; Nagelkerke SQ; Lissenberg-Thunnissen S; Koeleman CAM; Wuhrer M; van den Berg TK; Rispens T; Vidarsson G; Kuijpers TW
    J Immunol; 2017 Jul; 199(1):204-211. PubMed ID: 28566370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The homozygous FcgammaRIIIa-158V genotype is a risk factor for heparin-induced thrombocytopenia in patients with antibodies to heparin-platelet factor 4 complexes.
    Gruel Y; Pouplard C; Lasne D; Magdelaine-Beuzelin C; Charroing C; Watier H
    Blood; 2004 Nov; 104(9):2791-3. PubMed ID: 15191947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.